-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Onradivir
Category | Influenza Virus |
CAS | 2200336-20-3 |
Description | Onradivir is a significantly better anti-influenza virus agent. (Extracted from patent WO2021047437 A1) |
Product Information
Synonyms | Bicyclo[2.2.2]octane-2-carboxylic acid, 3-[[6-cyclopropyl-5-fluoro-2-(5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-yl)-4-pyrimidinyl]amino]-, (2S,3S)-; (2S,3S)-3-((6-Cyclopropyl-5-fluoro-2-(5-fluoro-1H-pyrazolo(3,4-b)pyridin-3-yl)-4-pyrimidinyl)amino)bicyclo(2.2.2)octane-2-carboxylic acid |
IUPAC Name | (2S,3S)-3-[[6-cyclopropyl-5-fluoro-2-(5-fluoro-2H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-yl]amino]bicyclo[2.2.2]octane-2-carboxylic acid |
Molecular Weight | 440.45 |
Molecular Formula | C22H22F2N6O2 |
Canonical SMILES | C1CC2CCC1C(C2NC3=NC(=NC(=C3F)C4CC4)C5=C6C=C(C=NC6=NN5)F)C(=O)O |
InChI | InChI=1S/C22H22F2N6O2/c23-12-7-13-18(29-30-19(13)25-8-12)21-27-17(11-5-6-11)15(24)20(28-21)26-16-10-3-1-9(2-4-10)14(16)22(31)32/h7-11,14,16H,1-6H2,(H,31,32)(H,25,29,30)(H,26,27,28)/t9?,10?,14-,16-/m0/s1 |
InChIKey | JCHDJLSIYWBAHI-ZWHBIUKWSA-N |
Purity | ≥98% (HPLC) |
Solubility | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
Appearance | Solid powder |
Storage | Store at -20°C |
Complexity | 721 |
Exact Mass | 440.17723029 |
Target | Influenza Virus |
XLogP3-AA | 3.9 |